NASDAQ:PDLI - PDL BioPharma, Inc.
$3.08
 $-0.06
-1.91%
12:40PM EDT
2019-07-22
PDL BioPharma, Inc., incorporated on July 24, 1986, seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company's segments include income generating assets and product sales. The income generating assets segment consists of royalties from issued patents in the United States and elsewhere, covering the humanization of antibodies, which it refers to as the Queen et al. patents; notes and other long-term receivables, royalty rights-at fair value and equity investments. The Company's product sales segment consists of revenue derived from Tekturna, Tekturna HCT, Rasilez and Rasilez HCT (collectively, the Noden Products or Tekturna) sales. The Company is focused on the acquisition of additional products, and expects to transact royalty transactions and debt transactions.Product SalesThe Company holds the worldwide rights to manufacture, market, and sell the branded prescription medicine product sold under the name Tekturna and Tekturna HCT in the United States, and Rasilez and Rasilez HCT in the rest of the world. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  PDLI     avg for
industry  
  avg for
sector  
42 stocks weight:  5. 84   217. 37   399. 45  
42 stocks rank:  4. 16 K 1. 27 K 716. 99  
# analyst opinions:  1. 00   13. 21   13. 71  

quick ratio:  8. 94   5. 49   1. 88  
current ratio:  11. 02   5. 87   2. 36  

ex-dividend date:     2016-06-01
target price low:  3. 00   83. 44   114. 90  
target price avg:  3. 00   106. 20   137. 90  
target price high:  3. 00   132. 30   158. 97  
1-yr high:  3. 85   111. 86   142. 57  
last close:  3. 14   86. 79   125. 44  
50-day avg:  3. 05   86. 68   122. 63  
200-day avg:  3. 12   89. 22   121. 38  
1-yr low:  2. 28   69. 78   100. 51  
volume:  679. 25 K 2. 62 M 3. 43 M
50-day avg volume:  1. 13 M 3. 20 M 4. 16 M
200-day avg volume:  1. 44 M 2. 99 M 4. 75 M

1-day return:  -2. 18 % -1. 30 % -0. 99 %
this week return:  0. 32 % 0. 45 % -0. 20 %
12-wk return:  -7. 65 % 0. 94 % 4. 84 %
52-wk return:  26. 38 % -1. 30 % 10. 55 %

enterprise value (EV):  141. 53 M 45. 10 B 122. 38 B
market cap:  378. 86 M 38. 96 B 108. 40 B
EBITDA:  2. 00 M 4. 20 B 8. 19 B
enterprise multiple (EV/EBITDA):  70. 66   5. 38   11. 93  
enterprise/revenue (EV/R):  1. 28   57. 92   10. 21  
total revenue:  110. 50 M 9. 91 B 39. 98 B
total debt:  128. 49 M 10. 90 B 17. 48 B
debt/equity:  18. 52   57. 18   120. 05  
net income (common):  -63. 78 M 2. 07 B 4. 05 B

shares outstanding:  120. 66 M 538. 09 M 1. 24 B
shares:  108. 16 M 548. 00 M 1. 22 B
shares short:  16. 26 M 10. 98 M 11. 87 M
shares short prior month:  16. 16 M 9. 32 M 12. 05 M
short ratio:  12. 27   5. 60   3. 34  
short % of float:  17. 49 % 6. 48 % 2. 64 %
total cash/share:  3. 04   10. 98   9. 19  
total cash:  366. 32 M 5. 93 B 6. 10 B
free cash flow:  47. 32 M 2. 92 B 4. 55 B
operating cash flow:  4. 61 M 3. 80 B 5. 78 B

book value:  5. 62   13. 35   27. 45  
price/book:  0. 56   4. 60   8. 78  
gross profits:  62. 06 M 7. 44 B 36. 13 B
operating margins:  -11. 70 % -308. 40 % -28. 55 %
EBITDA margins:  1. 81 % 13. 17 % 23. 38 %
profit margins:  -57. 72 % 10. 44 % 14. 18 %
gross margins:  54. 11 % 35. 80 % 55. 40 %

1-yr max volatility:  0. 00 % --- ---
1-yr mean volatility:  0. 00 % 1. 66 % 1. 03 %

1-yr EPS:  -0. 46   2. 10   4. 23  
forward EPS:  0. 14   3. 45   7. 10  
P/E:  -6. 89   1. 90   32. 10  
forward P/E:  22. 43   6. 46   15. 47  
PE/G:  -0. 09   0. 70   -0. 54  
growth:  79. 17 % 265. 63 % 79. 11 %
earnings high:  0. 04   0. 89   1. 68  
earnings avg:  0. 04   0. 70   1. 57  
earnings low:  0. 04   0. 46   1. 46  
revenue high:  31. 74 M 2. 57 B 11. 07 B
revenue avg:  31. 74 M 2. 51 B 10. 91 B
revenue low:  31. 74 M 2. 45 B 10. 73 B
earnings growth:  400. 00 % 12. 05 % 30. 99 %
1-qtr earnings growth:  317. 00 % 9. 70 % 30. 42 %
return on assets:  -0. 80 % -2. 34 % 5. 28 %
return on equity:  -8. 31 % -90. 08 % 133. 53 %
revenue growth:  -0. 10 % 265. 25 % 73. 68 %
revenue/share:  0. 79   12. 72   60. 04  

beta (1yr vs S&P500):  1. 32   1. 27   0. 91  
sharpe (1yr):  0. 73   0. 16   0. 77  

held % insiders:  2. 47 % 6. 06 % 3. 29 %
held % institutions:  95. 24 % 78. 22 % 69. 37 %

Research more with google or yahoo!
the data below are updated and re-published at 8pm EDT after each trading day

2019-07-21 : PDLI
.    101.439 =       101.439 :: --> INITIAL WEIGHT <--
.    - 0.456 =       100.983 :: earnings per-share addition
.                               --> FUNDAMENTALS <--
.    x 2.175 =       219.642 :: P/E factor
.    x 1.841 =       404.457 :: PE/G factor
.    x 1.752 =       708.603 :: beta factor
.    x 0.902 =       639.506 :: sharpe factor
.    x 2.121 =      1356.603 :: current ratio factor
.    x 1.061 =      1439.458 :: quick ratio factor
.     x 1.04 =      1496.967 :: short ratio factor
.    x 3.224 =       4826.35 :: earnings growth factor
.    x 1.022 =      4933.085 :: EV/R factor
.    x 1.003 =      4946.854 :: price-to-book factor
.    x 2.197 =     10866.997 :: EBITDA vs industry factor
.    x 0.949 =     10314.067 :: debt-to-revenue factor
.    x 1.151 =     11867.353 :: debt-to-equity factor
.                               --> PERFORMANCE <--
.    x 2.121 =       25168.2 :: sector+industry 1-year gains factor
.    x 1.009 =     25405.488 :: industry 12-weeks return factor
.    x 1.308 =     33227.547 :: industry 2-weeks return factor
.    x 1.024 =     34021.907 :: 5-day avg > 200-day avg
.    x 1.153 =     39239.952 :: 5-day avg > 50-day avg
.    x 0.986 =     38696.553 :: "drift" penalty 5 days ago
.    / 1.854 =     20874.945 :: overall "drift" factor
.    x 0.943 =     19675.358 :: largest single-day jump factor
.    x 0.071 =      1401.379 :: low price factor
.    x 0.313 =       439.303 :: notable returns + performance factor
.                               --> PROJECTIONS <--
.    x 0.726 =       319.045 :: forward EPS factor
.    x 0.901 =       287.308 :: forward P/E factor
.    x 1.185 =       340.378 :: industry recommendation factor
.    x 1.003 =       341.319 :: factor historical industry gain for week 29
.                               --> FINAL ADJUSTMENTS <--
.  quad root =         4.298 :: reduced for readability
.    + 1.538 =         5.837 :: add/subtract for investor sentiment
.                               --> FINAL WEIGHT <--
.                      5.837 :: FINAL WEIGHT for NASDAQ:PDLI


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org